Ozmosi | Dydrogesterone Drug Profile

Product Description

Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus. At therapeutic levels, dydrogesterone has no contraceptive effect as it does not inhibit or interfere with ovulation or the corpus luteum. Furthermore, dydrogesterone is non-androgenic, non-estrogenic, non-corticoid, non-anabolic and is not excreted as pregnanediol. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dydrogesterone#section=Pharmacology-and-Biochemistry)

Mechanisms of Action: PR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Abbott Laboratories
Company Location: Eastern America
Company CEO: Robert B. Ford
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Anorexia

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT06378268	ProGanOS	N/A	Recruiting	Pregnancy Outcomes\|Ovarian Cysts\|Follicular Cyst\|Pregnancy, Ovarian	2025-12-31	2024-04-27
ChiCTR2500096050	Study on the efficacy of different MHT protocols in intervening with cognitive function in perimenopausal and postmenopausal women based on fNIRS detection	N/A	Not yet recruiting	Dementia	2029-12-01
ChiCTR2500113652	ChiCTR2500113652	N/A	Not yet recruiting	Pregnancy Outcomes	2028-12-31
ChiCTR2500103211	ChiCTR2500103211	N/A	Not yet recruiting	Endometriosis	2028-01-31
ChiCTR2400094539	ChiCTR2400094539	N/A	Not yet recruiting	Infertility	2027-12-31
ChiCTR2500110611	ChiCTR2500110611	N/A	Not yet recruiting	Infertility	2027-10-01
ChiCTR2400091369	ChiCTR2400091369	N/A	Not yet recruiting	Injuries/wounds Unspecified	2027-06-30
NCT05847283	DPOS	N/A	Recruiting	Pregnancy Outcomes\|Pregnancy, Ovarian\|Abortion, Threatened\|Obstetric Labor, Premature\|Acute Respiratory Distress Syndrome	2027-05-31	2024-11-09	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
ChiCTR2500098020	ChiCTR2500098020	N/A	Recruiting	Infertility	2027-02-26
ChiCTR2400084571	ChiCTR2400084571	N/A	Not yet recruiting	Infertility	2026-12-31	2024-05-22	Treatments
ChiCTR2400079652	ChiCTR2400079652	N/A	Not yet recruiting	Depressive Disorder	2026-11-30	2024-01-11	Treatments
ACTRN12621000439842p	2006-7041-83/hah	N/A	Not yet recruiting	Leukemia	2026-08-03
NCT06952296	Daisy	N/A	Not yet recruiting	Endometriosis	2026-06-30	2025-08-27	Primary Endpoints\|Treatments
ChiCTR2400087131	ChiCTR2400087131	N/A	Not yet recruiting	Pregnancy Outcomes	2026-06-01	2024-07-22	Treatments
ChiCTR2400089666	ChiCTR2400089666	N/A	/Completed	Immune Complex Diseases\|Periodontal Pocket\|Periodontal Diseases\|Inflammation\|Tooth Loss\|Chronic Periodontitis	2026-04-30
ChiCTR2300074428	ChiCTR2300074428	N/A	Not yet recruiting	Endometrial Hyperplasia	2026-01-19	2023-08-08	Treatments
CTR20252416	CTR20252416	N/A	Completed	Menopause	2025-12-08	2025-12-21	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20252417	CTR20252417	N/A	Completed	Menopause	2025-11-04	2025-11-23	Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
ChiCTR2300077340	ChiCTR2300077340	N/A	Recruiting	Polycystic Ovary Syndrome	2025-11-01	2024-05-26	Treatments
CTR20252451	CTR20252451	N/A	Completed	Menopause	2025-10-08	2025-10-28	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20252555	CTR20252555	N/A	Completed	Menopause	2025-09-20	2025-11-16	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
NCT06546397	PRO2023-3733	P1	Recruiting	Pregnancy Outcomes\|Gynatresia	2025-09-30	2025-08-29	Primary Endpoints\|Treatments
NCT03859921	UW 18-594	P3	Recruiting	Infertility	2025-12-30	2025-06-13	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
2023-509919-89-00	2023-509919-89-00	P4	Recruiting	Infertility, Female\|Infertility, Male	2027-10-01	2025-05-02	Treatments
2024-513998-48-00	CS-10459	P4	Recruiting	Unknown	2026-06-30	2025-05-02	Treatments

Recent News Events

Date	Type	Title
10/10/2023	News Article	Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.
10/03/2023	News Article	Dydrogesterone API Market Is Likely to Experience Incredible Growth in Near Future By 2029
10/03/2023	News Article	Oral Dydrogesterone Market Size, Trends & Opportunities, Research Report 2023 -2031
09/26/2023	News Article	Single Axis Gyroscope Market Latest Trends and Growing Business Opportunities 2023 to 2029- TDK , Murata Manufacturing , TE Connectivity , Analog Devices

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Dydrogesterone

Alternative Names: dydrogesterone, gynorest Clinical Status: Inactive Latest Update: 2025-12-18 Latest Update Note: Clinical Trial Update